Expression Of BORIS In Colon Carcinoma OfⅡ、Ⅲ Stage And Its Prognosis

Brother of the regulator of the imprinted site(BORIS) or CTCFL is an11zincfinger protein,which is considered to be a new oncogene.It is a paralogue of CCTC-binding factor(CTCF),generated by a duplication event.BORIS is highly expressed in primary spermatocytes, oocytes and in4cells embryos at early stages of preimplantation development. although it is silenced at later stages of spermatogenesis.BORIS has neither been found in normal human tissuesor cells nor has been detected at very low levels. The expression of the BORIS gene is controlled by DNA-methylation, while its activation requires the demethylation of its promoter. expression of BORIS in cancers is due to the hypomethylation of its promoter.it’s differently expressed in different cancers.so are the relationship between the clinical pathlogical parameters. This study aims to analysis the exact relationship between the clinical pathlogical parameters in mRNA and protein level by RT-PCR an immunohistochemistry,and find whether the BORIS and other factors are independent dangerous factor for the prognosisObjective:to detect the expression of BORIS in colon carcinoma (patients in Ⅱ and Ⅲ stages by TNM staging) and normal tissues,and analysis the relationship between the expression of BORIS and its clinical, pathological parameters and median survival time, internalize the clinical and pathological parameters into Cox model, analysis whether the BORIS and other factors are independent dangerous factor for the prognosis, search for the new target gene for treating colon carcinoma.Methods:select the patients’ information and tissues refer to some standard, RT-PCR and immunohistochemistry were adopted to check the expression of BORIS in50colon carcinoma and20normal colon tissues. The relationship between BORIS and other pathlogical parameters will be shown(analysised by SPSS19.0software);encode the information according to the procedure, then set up the FOXBASE,the Cox model and Kaplain-Mainer method will be used.Results:no expression of BORIS was founded in normal colon tissues, but in colon carcinoma,the BORIS were abundantly expressed,the expression of BORIS has no relationship with anatomic sites (mRNA:t=1.318.P<0.05;Protein:X2=2.383,P＞0.05),histic sites(mRNA:t=1.342.P>0.05;Protein:X2=1.383).however,it’s correlated with the differentiation grade of histology (mRNA:t=2.174.P<0.05;Protein:X2=4.906, P<0.05;r=0.533, P<0.05),metastasis of lymph nodes(mRNA:t=2.246.P<0.05; Protein:X2=1.562, P<0.05;r=0.536, P<0.05),tumor sizes(mRNA:t=2.157.P<0.05;Protein:X2=24.532, P<0.05;r=0.606, P<0.05) and median survival time(X2=4.067,P=0.044).but the median survival time of positively expressed patients is lower than the negatively expressed ones.according to the scores(Wald) metastasis lymph nodes,histology grade and BORIS expression are independent dangerous factor for the prognosis.Conclusion:re-expression of BORIS in colon carcinoma may participate the carcinogenesis, include the tumor growth, early metastatis and cell differentiation. The survival time of Patients who express BORIS is lower than negatively expressed ones. BORIS might be a new tumor marker in the new diagnosis of early metastasis of lymph nodes and judge ment of prognosis of colon carcinoma.